TTRA supports Nirtek’s mission to prevent heart attacks and save lives

The MTPConnect Podcast

MTPConnect에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 MTPConnect 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

2y ago 28:30

MP3•에피소드 홈

Heart attack caused by rupture of unstable plaque in the coronary arteries is the number one cause of death worldwide.

Melbourne-based medtech company Nirtek, is using laser technology discovered at the Baker Heart and Diabetes Institute, to develop the first intra-coronary guidewire device for the detection of unstable plaque to prevent heart attacks and save lives. Nirtek’s device has been awarded funding through MTPConnect’s Targeted Translation Research Accelerator program for Diabetes & Cardiovascular Disease, made possible by the Medical Research Future Fund.

MTPConnect hosts Caroline Duell and Lauren Kelly, Senior Director of the TTRA Program are joined by Nirtek’s CEO Matthew Hoskin, who shares the challenges of their medtech journey as the company prepares for a capital raise and works towards creating a prototype for clinical trials. Matthew also explains the value of the support provided by the Medical Device Partnering Program (MDPP), a TTRA venture partner, and MDPP’s Olivia White joins the discussion.

172 에피소드